Literature DB >> 30894366

Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression.

Tania Habib1, S Alice Long1, Peter L Samuels1, Archana Brahmandam2, Megan Tatum1, Andrew Funk1, Anne M Hocking1, Karen Cerosaletti1, Michael T Mason1, Elizabeth Whalen3, David J Rawlings2,4, Carla Greenbaum3, Jane H Buckner5.   

Abstract

Multiple studies of B- and T-cell compartments and their response to stimuli demonstrate alterations in established type 1 diabetes (T1D). Yet it is not known whether these alterations reflect immune mechanisms that initiate islet autoimmunity, promote disease progression, or are secondary to disease. To address these questions, we used samples from the TrialNet Pathway to Prevention study to investigate T-cell responses to interleukin (IL)-2 and regulatory T cell-mediated suppression, the composition of the B-cell compartment, and B-cell responses to B-cell receptor and IL-21 receptor engagement. These studies revealed stage-dependent T- and B-cell functional and immune phenotypes; namely, early features that differentiate autoantibody-positive at-risk first-degree relatives (FDRs) from autoantibody-negative FDRs and persisted through clinical diagnosis; late features that arose at or near T1D diagnosis; and dynamic features that were enhanced early and blunted at later disease stages, indicating evolving responses along the continuum of T1D. We further explored how these specific phenotypes are influenced by therapeutic interventions. Our integrated studies provide unique insights into stable and dynamic stage-specific immune states and define novel immune phenotypes of potential clinical relevance.
© 2019 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30894366      PMCID: PMC6610015          DOI: 10.2337/db18-1081

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  59 in total

1.  Assessment of suppressive capacity by human regulatory T cells using a reproducible, bi-directional CFSE-based in vitro assay.

Authors:  Anya Schneider; Jane H Buckner
Journal:  Methods Mol Biol       Date:  2011

2.  β cell death and dysfunction during type 1 diabetes development in at-risk individuals.

Authors:  Kevan C Herold; Sahar Usmani-Brown; Tara Ghazi; Jasmin Lebastchi; Craig A Beam; Melena D Bellin; Michel Ledizet; Jay M Sosenko; Jeffrey P Krischer; Jerry P Palmer
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

Review 3.  The pathogenesis and natural history of type 1 diabetes.

Authors:  Mark A Atkinson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

4.  The BANK1 SLE-risk variants are associated with alterations in peripheral B cell signaling and development in humans.

Authors:  Elizabeth M Dam; Tania Habib; Janice Chen; Andrew Funk; Veronika Glukhova; Mel Davis-Pickett; Shan Wei; Richard James; Jane H Buckner; Karen Cerosaletti
Journal:  Clin Immunol       Date:  2016-11-02       Impact factor: 3.969

Review 5.  Targeting B cells in treatment of autoimmunity.

Authors:  S Elizabeth Franks; Andrew Getahun; P Mark Hogarth; John C Cambier
Journal:  Curr Opin Immunol       Date:  2016-10-05       Impact factor: 7.486

6.  Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus.

Authors:  Sergey V Kozyrev; Anna-Karin Abelson; Jerome Wojcik; Ammar Zaghlool; M V Prasad Linga Reddy; Elena Sanchez; Iva Gunnarsson; Elisabet Svenungsson; Gunnar Sturfelt; Andreas Jönsen; Lennart Truedsson; Bernardo A Pons-Estel; Torsten Witte; Sandra D'Alfonso; Nadia Barizzone; Nadia Barrizzone; Maria Giovanna Danieli; Carmen Gutierrez; Ana Suarez; Peter Junker; Helle Laustrup; Maria Francisca González-Escribano; Javier Martin; Hadi Abderrahim; Marta E Alarcón-Riquelme
Journal:  Nat Genet       Date:  2008-01-20       Impact factor: 38.330

7.  Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance.

Authors:  M I Vargas-Rojas; J C Crispín; Y Richaud-Patin; J Alcocer-Varela
Journal:  Lupus       Date:  2008-04       Impact factor: 2.911

Review 8.  Autoimmune manifestations in primary immune deficiencies.

Authors:  Guillaume Bussone; Luc Mouthon
Journal:  Autoimmun Rev       Date:  2008-11-24       Impact factor: 9.754

9.  Loss of B-Cell Anergy in Type 1 Diabetes Is Associated With High-Risk HLA and Non-HLA Disease Susceptibility Alleles.

Authors:  Mia J Smith; Marynette Rihanek; Clive Wasserfall; Clayton E Mathews; Mark A Atkinson; Peter A Gottlieb; John C Cambier
Journal:  Diabetes       Date:  2018-01-17       Impact factor: 9.461

10.  Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes.

Authors:  Xinyu Xu; Yun Shi; Yun Cai; Qingqing Zhang; Fan Yang; Heng Chen; Yong Gu; Mei Zhang; Liping Yu; Tao Yang
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

View more
  14 in total

1.  Costimulation Blockade Disrupts CD4+ T Cell Memory Pathways and Uncouples Their Link to Decline in β-Cell Function in Type 1 Diabetes.

Authors:  Martin Eichmann; Roman Baptista; Richard J Ellis; Susanne Heck; Mark Peakman; Craig A Beam
Journal:  J Immunol       Date:  2020-05-13       Impact factor: 5.422

Review 2.  Endotypes in T1D: B lymphocytes and early onset.

Authors:  Mia J Smith; John C Cambier; Peter A Gottlieb
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-08       Impact factor: 3.243

3.  Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes.

Authors:  Jennie H M Yang; Kirsten A Ward-Hartstonge; Daniel J Perry; J Lori Blanchfield; Amanda L Posgai; Alice E Wiedeman; Kirsten Diggins; Adeeb Rahman; Timothy I M Tree; Todd M Brusko; Megan K Levings; Eddie A James; Sally C Kent; Cate Speake; Dirk Homann; S Alice Long
Journal:  Eur J Immunol       Date:  2022-01-28       Impact factor: 5.532

4.  Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity.

Authors:  Katharina Lambert; Keagan G Moo; Azlann Arnett; Gautam Goel; Alex Hu; Kaitlin J Flynn; Cate Speake; Alice E Wiedeman; Vivian H Gersuk; Peter S Linsley; Carla J Greenbaum; S Alice Long; Rebecca Partridge; Jane H Buckner; Bernard Khor
Journal:  Sci Transl Med       Date:  2022-01-12       Impact factor: 19.319

5.  The Childhood Vaccination Schedule and the Lack of Association With Type 1 Diabetes.

Authors:  Jason M Glanz; Christina L Clarke; Matthew F Daley; Jo Ann Shoup; Simon J Hambidge; Joshua T B Williams; Holly C Groom; Elyse O Kharbanda; Nicola P Klein; Lisa A Jackson; Bruno J Lewin; David L McClure; Stanley Xu; Frank DeStefano
Journal:  Pediatrics       Date:  2021-12-01       Impact factor: 9.703

6.  Insulin Receptor-Expressing T Cells Appear in Individuals at Risk for Type 1 Diabetes and Can Move into the Pancreas in C57BL/6 Transgenic Mice.

Authors:  Neha Nandedkar-Kulkarni; Emily Esakov; Brigid Gregg; Mark A Atkinson; Douglas G Rogers; James D Horner; Kanakadurga Singer; Steven K Lundy; Jamie L Felton; Tasneem Al-Huniti; Andrea Nestor Kalinoski; Michael P Morran; Nirdesh K Gupta; James D Bretz; Swapnaa Balaji; Tian Chen; Marcia F McInerney
Journal:  J Immunol       Date:  2021-03-03       Impact factor: 5.422

Review 7.  The Remission Phase in Type 1 Diabetes: Role of Hyperglycemia Rectification in Immune Modulation.

Authors:  Rong Tang; Ting Zhong; Chao Wu; Zhiguang Zhou; Xia Li
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-03       Impact factor: 5.555

8.  Uncovering Pathways to Personalized Therapies in Type 1 Diabetes.

Authors:  Peter S Linsley; Carla J Greenbaum; Gerald T Nepom
Journal:  Diabetes       Date:  2021-04       Impact factor: 9.461

Review 9.  Identifying the 'Achilles heel' of type 1 diabetes.

Authors:  M Battaglia; J H Buckner; M K Levings; S J Richardson; F S Wong; T I Tree
Journal:  Clin Exp Immunol       Date:  2021-02-22       Impact factor: 4.330

Review 10.  What Have Slow Progressors Taught Us About T1D-Mind the Gap!

Authors:  Kathleen M Gillespie; Anna E Long
Journal:  Curr Diab Rep       Date:  2019-09-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.